Schulman Associates buys Florida IRB

- Last updated on GMT

Related tags: Institutional review board

Cincinnati, US-based Schulman Associates Institutional Review Board (IRB) has bought Florida counterpart Independent Investigational Review Board (IIR) to broaden its offering for Pharmas and CROs.

The deal, terms of which were not provided, will add IIR’s Association for the Accreditation of Human Research Protection Programs (AAHRPP) office in Plantation to Schulman’s network and is the firm’s most significant investment since November 2009​ when it established an office in Toronto, Canada.

Current IIR CEO Kim Lerner, who will leave the company as a result of the deal, said that: “Joining with Schulman allows Independent to provide the advantages of enhanced WebPortal and IT features to our established customer base​.”

IIR appears to have a broad customer base. Last month the firm was named as the reviewer of a study examining if a demal graft product can be used to improve the appearance of hair transplant patients.

Related news

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars